Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. Equipment
  3. usa california
  4. immune suppression
Show results for
Products

Companies


Refine by
Locations
Back to All Locations

  • USA
  • California
Brands

  • immune-onc
  • dxterity
  • ibio

Immune Suppression Equipment Supplied In Usa California

8 equipment items found
In CaliforniaAvailable In CaliforniaNear California

Synthetic mRNA

Synthetic mRNA

Manufactured by:Brooklyn ImmunoTherapeutics (BTX)   based inSan Diego, CALIFORNIA (USA)
Expressing reprogramming proteins by repeated transfection with protein-encoding RNA could avoid the limitations of both DNA and protein-based reprogramming techniques. However, transfection with long, in vitro-transcribed RNA triggers a potent innate immune response in human cells, even when the RNA is capped and polyadenylated to mimic eukaryotic mRNA. To address this problem, ...
CONTACT SUPPLIER

DxTerity - Immunity Assessment Test Kit

DxTerity - Immunity Assessment Test Kit

Manufactured by:DxTerity Diagnostics Inc.   based inRancho Dominguez, CALIFORNIA (USA)
The DxTerity Immunity Assessment Test measures COVID-19 neutralizing antibody levels from a small sample of blood. Knowing your neutralizing antibody levels can help you assess your risk of future symptomatic ...
CONTACT SUPPLIER

Immune-Onc - Model IO-106 - (Anti-LAIR1) Mechanisms of Action Program

Immune-Onc - Model IO-106 - (Anti-LAIR1) Mechanisms of Action Program

Manufactured by:Immune-Onc Therapeutics, Inc.   based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is evaluating IO-106, an antagonist antibody targeting LAIR1, an immune inhibitory receptor. The company’s preclinical research supports the proposed mechanisms of action of IO-106 and its evaluation as a potential treatment for solid ...
CONTACT SUPPLIER

Immune-Onc - Model IO-108 - (Anti-LILRB2) Mechanisms of Action Program

Immune-Onc - Model IO-108 - (Anti-LILRB2) Mechanisms of Action Program

Manufactured by:Immune-Onc Therapeutics, Inc.   based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is evaluating IO-108, an antagonist antibody targeting the myeloid checkpoint, LILRB2 (also known as ILT4). The U.S. FDA has cleared the IND application for IO-108 as a potential therapy for solid tumors. The company expects to begin clinical trials with IO-108 in the second half of ...
CONTACT SUPPLIER

Human Derived Mixed Cytokines

Human Derived Mixed Cytokines

Manufactured by:Brooklyn ImmunoTherapeutics (BTX)   based inSan Diego, CALIFORNIA (USA)
Why human derived? Brooklyn has developed a powerful method to create complex cytokine mixtures derived from a human source. Cytokines are powerful immune factors that play an essential role in T cell signaling, activation, proliferation, and tumor-fighting responses. We know cytokines may induce beneficial reactions in cancer patients. To date, available cytokine therapies have been recombinant ...
CONTACT SUPPLIER

Model IRX-2 - Human-Derived Mixed Cytokine

Model IRX-2 - Human-Derived Mixed Cytokine

Manufactured by:Brooklyn ImmunoTherapeutics (BTX)   based inSan Diego, CALIFORNIA (USA)
IRX-2 is a human-derived mixed cytokine product containing more than 29 cytokines that promote or enhance a complex immune response. Scientists are developing IRX-2 as a cancer immunotherapy. IRX-2 is administered as a subcutaneous injection around lymph node beds near the tumor target. IRX-2 is produced under cGMP (current good manufacturing process) conditions following stimulation of a ...
CONTACT SUPPLIER

IBIO - Model 101 - Immuno Oncology Therapeutics

IBIO - Model 101 - Immuno Oncology Therapeutics

Manufactured by:Ibio, Inc.   based inBryan, TEXAS (USA)
This is in part due to dynamics in the tumor microenvironment, wherein regulatory T cells [Tregs] proliferate and suppress the immune responses to tumor cells. The Treg is a type of T cell that is important in preventing autoimmunity by keeping effector T cells [Teffs] “in-check” to prevent destruction of healthy tissues. However, around tumors, Tregs ...
CONTACT SUPPLIER

Immune-Onc - Model IO-202 - (Anti-LILRB4) Mechanisms of Action in Hematologic Malignancies Program

Immune-Onc - Model IO-202 - (Anti-LILRB4) Mechanisms of Action in Hematologic Malignancies Program

Manufactured by:Immune-Onc Therapeutics, Inc.   based inPalo Alto, CALIFORNIA (USA)
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia ...
CONTACT SUPPLIER
  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT